Drug Development.

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Extracellular vesicles (EVs) are emerging neurotherapeutics for Alzheimer's disease.
• Glutamate excitotoxicity is a major driver of neurodegeneration in Alzheimer's disease.
• Investigating novel EVs from human glial progenitor cells (hGPCs) for neuroprotection.

Purpose of the Study:

• To investigate the neuroprotective mechanisms of EVs derived from human glial progenitor cells (hGPCs).
• To assess the efficacy of EV-hGPCs in a glutamate excitotoxicity model.
• To identify the molecular pathways involved in the neuroprotective effects of EV-hGPCs.

Main Methods:

• EVs isolated from hGPC conditioned medium via ultracentrifugation.
• Glutamate excitotoxicity model using primary cortical neuron cultures from rat pups.
• Proteomic analysis of EV-hGPCs using LC-MS/MS.
• Bioinformatic analysis of protein pathways using String 8.0 and KEGG databases.
• Inhibitor assays using AS605240 to probe the PI3K-Akt signaling pathway.

Main Results:

• Glutamate exposure decreased viable neurons by 37.5%.
• EV-hGPCs significantly increased neuronal survival rates (20% at 3 μg/mL, control levels at 10 μg/mL).
• Proteomic analysis identified the PI3K-Akt signaling pathway as highly represented in EV-hGPCs.
• Inhibitor assays confirmed that EV-hGPC neuroprotection is mediated by PI3K-Akt pathway activation.

Conclusions:

• EV-hGPCs demonstrate significant neuroprotective effects in a glutamate excitotoxicity model.
• The neuroprotective action of EV-hGPCs is attributed to the activation of the PI3K-Akt signaling pathway.
• These findings support the potential of EV-hGPCs as a therapeutic agent for Alzheimer's disease.